精密診断市場の2030年までの予測：タイプ別、用途別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の精密診断市場は2023年に793億米ドルを占め、予測期間中のCAGRは14.6％で成長し、2030年には2,057億米ドルに達すると予測されています。

非常に精密でカスタマイズされた医療検査を可能にする改良された診断技術の市場は、精密診断市場として知られています。精密診断には、プロテオミクス、ゲノミクス、分子診断学などの高度な手法を用いた患者サンプルの分子分析が含まれます。この手法により、遺伝子変異、バイオマーカー、特定の疾患に関連するその他の分子指標を正確に特定することができます。

世界保健機関（WHO）によると、2021年5月、世界中で163,312,429人がCOVID-19の影響を受けています。

ヘルスケア意識の向上

正確な診断が治療結果にもたらす画期的な効果に対する患者や医療従事者の意識は高まっています。疾患の早期発見、オーダーメイドの治療レジメン、より良い患者の転帰の可能性などの利点に気づく人が増えています。さらに、ますます多くの洗練された患者が、分子レベルでの健康状態を深く理解できる最先端の診断ツールへのアクセスを求めています。

高額な初期投資

先端技術の導入には、特殊な機械、インフラ、熟練した従業員への多額の先行投資が必要です。次世代シーケンシングや分子プロファイリングなどがその例です。これらの高額な初期費用は、医療施設や診断ラボにとって経済的な課題となり、特定の精密診断サービスへの患者のアクセスを制限する可能性があります。しかし、技術購入だけにとどまらず、医療専門家への徹底したトレーニングコースが含まれるため、経済的負担はさらに大きくなります。

慢性疾患の蔓延

がん、心血管疾患、神経疾患などの疾病の世界の負担の増加により、正確でタイムリーな診断ツールがますます必要となってきています。様々な慢性疾患に関連する特定の遺伝子変異、バイオマーカー、分子シグネチャーの同定は、最先端の分子技術やオーダーメイド医療技術を含む精密診断によって可能となります。さらに、これらの疾患は専門的な治療を必要とすることが多いため、正確で綿密な診断は介入を成功させ、患者の転帰を改善するために不可欠です。

データプライバシーとセキュリティへの懸念

精密診断では、遺伝子や分子データを含む極めてセンシティブな患者情報の収集と解析が必要となるため、強固なデータ保護対策の確保は極めて重要です。患者や医療提供者は、個人健康情報の悪用、データ漏洩、不正アクセスの可能性を懸念しています。しかし、これらの問題に対処するためには、GDPRやHIPAAなどのデータ保護法を厳格に遵守する必要があり、サイバーセキュリティ・インフラに多額の出費が必要となります。

COVID-19の影響：

パンデミックは迅速かつ正確な診断の重要性を強調したが、緊急性のない診断処置の遅れとCOVID-19検査へのリソースの振り向けが混乱を招いた。業界では分子診断薬、特にPCRベースの検査に対する需要が急増したが、サプライチェーンの混乱と病院インフラの過負荷が問題となった。従来の診断環境も遠隔医療や遠隔診断への重点シフトの影響を受けた。

予測期間中、遺伝子検査分野が最大となる見込み

精密医療の普及に伴い、遺伝子検査分野が最大の市場シェアを占めています。分子プロファイリングや次世代シーケンシングなどの遺伝子検査に対する需要が急速に高まっています。個人の遺伝子組成は、これらの検査によって完全に認識することができ、特定の遺伝的差異、病気のかかりやすさ、可能性のある治療反応を検出することができます。さらに、病気の診断、リスク評価、治療計画のための遺伝子検査の使用は、遺伝性疾患の頻度の上昇と個別化ヘルスケアに対する意識の高まりによって推進されています。

予測期間中にCAGRが最も高くなると予想されるのは腫瘍学分野です。

分子検査、リキッドバイオプシー、ゲノムプロファイリングにより、さまざまながん種に関連する特定の遺伝的変化やバイオマーカーの特定が可能になったため、腫瘍学分野は急速に拡大しています。この精度の高さにより、腫瘍医は各患者の腫瘍固有の遺伝子プロファイルに基づいて治療計画をカスタマイズすることで、治療成績を最適化することができます。がんの世界の有病率の上昇と、その分子基盤に対する理解の深まりにより、腫瘍学のための正確な診断技術がより求められています。

最大のシェアを持つ地域

がんや心血管障害を含む慢性疾患の有病率の上昇により、高度で正確な診断ツールに対する需要が増加しているため、アジア太平洋地域が予測期間中、市場で最大のシェアを占めると予想されます。また、同地域では中流階級の人口が増加し、ヘルスケアの専門知識も向上しており、特に予防医療に重点が置かれています。さらに、より良い患者の転帰のためにオーダーメイドで的を絞った介入を行う精密診断の考え方は、ヘルスケアの観点におけるこの動きに沿ったものです。

CAGRが最も高い地域：

アジア太平洋地域は、テクノロジーの急速な進歩とヘルスケア・サービスの利用可能性の拡大により、収益性の高い成長を遂げています。中国、日本、インドのような国々は、研究開発、インフラ、ヘルスケアに多額の投資を行い、最先端の診断技術の導入に有利な環境を提供しています。アジア太平洋地域は、引き続きヘルスケアインフラの開拓を優先し、研究開発とイノベーションに投資し、精密医療へのパラダイムシフトを経験することで、世界規模での精密診断市場の成長と拡大を支える大きな力となることは間違いないです。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の精密診断市場：タイプ別

• 消費者への直接テスト
• 難解なテスト
• 遺伝子検査
• その他のタイプ

第6章 世界の精密診断市場：用途別

• 心臓血管
• 免疫学
• オンコロジー
• 呼吸器疾患
• その他の用途

第7章 世界の精密診断市場：エンドユーザー別

• 臨床検査室
• ホームケア
• 病院
• その他のエンドユーザー

第8章 世界の精密診断市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Abbott
• Bayer AG
• Koninklijke Philips N.V.
• Lantheus Medical Imaging, Inc.
• Novartis AG
• QIAGEN
• Quest Diagnostics Incorporated
• Sanofi
• Siemens Healthineers AG
• Swiss Precision Diagnostics GmbH

List of Tables

• Table 1 Global Precision Diagnostics Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Precision Diagnostics Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Precision Diagnostics Market Outlook, By Direct to Consumer Tests (2021-2030) ($MN)
• Table 4 Global Precision Diagnostics Market Outlook, By Esoteric Tests (2021-2030) ($MN)
• Table 5 Global Precision Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
• Table 6 Global Precision Diagnostics Market Outlook, By Other Types (2021-2030) ($MN)
• Table 7 Global Precision Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 8 Global Precision Diagnostics Market Outlook, By Cardiovascular (2021-2030) ($MN)
• Table 9 Global Precision Diagnostics Market Outlook, By Immunology (2021-2030) ($MN)
• Table 10 Global Precision Diagnostics Market Outlook, By Oncology (2021-2030) ($MN)
• Table 11 Global Precision Diagnostics Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 12 Global Precision Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 13 Global Precision Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 14 Global Precision Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 15 Global Precision Diagnostics Market Outlook, By Homecare (2021-2030) ($MN)
• Table 16 Global Precision Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 17 Global Precision Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 18 North America Precision Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 19 North America Precision Diagnostics Market Outlook, By Type (2021-2030) ($MN)
• Table 20 North America Precision Diagnostics Market Outlook, By Direct to Consumer Tests (2021-2030) ($MN)
• Table 21 North America Precision Diagnostics Market Outlook, By Esoteric Tests (2021-2030) ($MN)
• Table 22 North America Precision Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
• Table 23 North America Precision Diagnostics Market Outlook, By Other Types (2021-2030) ($MN)
• Table 24 North America Precision Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 25 North America Precision Diagnostics Market Outlook, By Cardiovascular (2021-2030) ($MN)
• Table 26 North America Precision Diagnostics Market Outlook, By Immunology (2021-2030) ($MN)
• Table 27 North America Precision Diagnostics Market Outlook, By Oncology (2021-2030) ($MN)
• Table 28 North America Precision Diagnostics Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 29 North America Precision Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 30 North America Precision Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 31 North America Precision Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 32 North America Precision Diagnostics Market Outlook, By Homecare (2021-2030) ($MN)
• Table 33 North America Precision Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 34 North America Precision Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 35 Europe Precision Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 36 Europe Precision Diagnostics Market Outlook, By Type (2021-2030) ($MN)
• Table 37 Europe Precision Diagnostics Market Outlook, By Direct to Consumer Tests (2021-2030) ($MN)
• Table 38 Europe Precision Diagnostics Market Outlook, By Esoteric Tests (2021-2030) ($MN)
• Table 39 Europe Precision Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
• Table 40 Europe Precision Diagnostics Market Outlook, By Other Types (2021-2030) ($MN)
• Table 41 Europe Precision Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 42 Europe Precision Diagnostics Market Outlook, By Cardiovascular (2021-2030) ($MN)
• Table 43 Europe Precision Diagnostics Market Outlook, By Immunology (2021-2030) ($MN)
• Table 44 Europe Precision Diagnostics Market Outlook, By Oncology (2021-2030) ($MN)
• Table 45 Europe Precision Diagnostics Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 46 Europe Precision Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 47 Europe Precision Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 48 Europe Precision Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 49 Europe Precision Diagnostics Market Outlook, By Homecare (2021-2030) ($MN)
• Table 50 Europe Precision Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 51 Europe Precision Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 52 Asia Pacific Precision Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 53 Asia Pacific Precision Diagnostics Market Outlook, By Type (2021-2030) ($MN)
• Table 54 Asia Pacific Precision Diagnostics Market Outlook, By Direct to Consumer Tests (2021-2030) ($MN)
• Table 55 Asia Pacific Precision Diagnostics Market Outlook, By Esoteric Tests (2021-2030) ($MN)
• Table 56 Asia Pacific Precision Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
• Table 57 Asia Pacific Precision Diagnostics Market Outlook, By Other Types (2021-2030) ($MN)
• Table 58 Asia Pacific Precision Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 59 Asia Pacific Precision Diagnostics Market Outlook, By Cardiovascular (2021-2030) ($MN)
• Table 60 Asia Pacific Precision Diagnostics Market Outlook, By Immunology (2021-2030) ($MN)
• Table 61 Asia Pacific Precision Diagnostics Market Outlook, By Oncology (2021-2030) ($MN)
• Table 62 Asia Pacific Precision Diagnostics Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 63 Asia Pacific Precision Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 64 Asia Pacific Precision Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 65 Asia Pacific Precision Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 66 Asia Pacific Precision Diagnostics Market Outlook, By Homecare (2021-2030) ($MN)
• Table 67 Asia Pacific Precision Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 68 Asia Pacific Precision Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 69 South America Precision Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 70 South America Precision Diagnostics Market Outlook, By Type (2021-2030) ($MN)
• Table 71 South America Precision Diagnostics Market Outlook, By Direct to Consumer Tests (2021-2030) ($MN)
• Table 72 South America Precision Diagnostics Market Outlook, By Esoteric Tests (2021-2030) ($MN)
• Table 73 South America Precision Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
• Table 74 South America Precision Diagnostics Market Outlook, By Other Types (2021-2030) ($MN)
• Table 75 South America Precision Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 76 South America Precision Diagnostics Market Outlook, By Cardiovascular (2021-2030) ($MN)
• Table 77 South America Precision Diagnostics Market Outlook, By Immunology (2021-2030) ($MN)
• Table 78 South America Precision Diagnostics Market Outlook, By Oncology (2021-2030) ($MN)
• Table 79 South America Precision Diagnostics Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 80 South America Precision Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 81 South America Precision Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 82 South America Precision Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 83 South America Precision Diagnostics Market Outlook, By Homecare (2021-2030) ($MN)
• Table 84 South America Precision Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 85 South America Precision Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 86 Middle East & Africa Precision Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 87 Middle East & Africa Precision Diagnostics Market Outlook, By Type (2021-2030) ($MN)
• Table 88 Middle East & Africa Precision Diagnostics Market Outlook, By Direct to Consumer Tests (2021-2030) ($MN)
• Table 89 Middle East & Africa Precision Diagnostics Market Outlook, By Esoteric Tests (2021-2030) ($MN)
• Table 90 Middle East & Africa Precision Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
• Table 91 Middle East & Africa Precision Diagnostics Market Outlook, By Other Types (2021-2030) ($MN)
• Table 92 Middle East & Africa Precision Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 93 Middle East & Africa Precision Diagnostics Market Outlook, By Cardiovascular (2021-2030) ($MN)
• Table 94 Middle East & Africa Precision Diagnostics Market Outlook, By Immunology (2021-2030) ($MN)
• Table 95 Middle East & Africa Precision Diagnostics Market Outlook, By Oncology (2021-2030) ($MN)
• Table 96 Middle East & Africa Precision Diagnostics Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
• Table 97 Middle East & Africa Precision Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 98 Middle East & Africa Precision Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 99 Middle East & Africa Precision Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 100 Middle East & Africa Precision Diagnostics Market Outlook, By Homecare (2021-2030) ($MN)
• Table 101 Middle East & Africa Precision Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 102 Middle East & Africa Precision Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Precision Diagnostics Market is accounted for $79.3 billion in 2023 and is expected to reach $205.7 billion by 2030 growing at a CAGR of 14.6% during the forecast period. The market for improved diagnostic technologies that enable very precise and customized medical testing is known as the "precision diagnostics market." Precision diagnostics entails the molecular analysis of patient samples using advanced methods, including proteomics, genomics, and molecular diagnostics. With this method, genetic variants, biomarkers, and other molecular indicators linked to certain diseases can be precisely identified.

According to the World Health Organization (WHO), in May 2021, 163,312,429 people worldwide were affected by COVID-19.

Market Dynamics:

Driver:

Increasing healthcare awareness

Patients and healthcare professionals' awareness of the revolutionary effect accurate diagnosis can have on treatment results is growing. An increasing number of people are becoming aware of the benefits of early disease detection, customized treatment regimens, and the possibility of better patient outcomes. Additionally, more and more sophisticated patients are asking for access to state-of-the-art diagnostic tools that can offer an in-depth understanding of their molecular health.

Restraint:

High upfront costs

Advanced technology adoption requires large upfront investments in specialized machinery, infrastructure, and skilled employees. Some instances of these are next-generation sequencing and molecular profiling. These higher initial costs might pose an economic challenge for medical facilities, and diagnostic labs and potentially restrict patient access to specific precision diagnostic services. However, the financial burden is further increased by the fact that the expenses extend beyond the purchase of technology and involve thorough training courses for medical professionals.

Opportunity:

Growing prevalence of chronic diseases

Accurate and timely diagnostic tools are becoming more and more necessary due to the rising worldwide burden of diseases like cancer, cardiovascular diseases, and neurological disorders. The identification of certain genetic mutations, biomarkers, and molecular signatures associated with a range of chronic conditions is made possible by precision diagnostics, which includes cutting-edge molecular technology and customized medicine techniques. Additionally, accurate and thorough diagnoses are essential for successful intervention and better patient outcomes since these illnesses often require specialized therapies.

Threat:

Data privacy and security concerns

Ensuring strong data protection measures is crucial because precision diagnostics requires the collection and analysis of extremely sensitive patient information, including genetic and molecular data. Patients and healthcare providers are concerned about the possibility of misuse, data breaches, and unauthorized access to personal health information. However, strict adherence to data protection laws, such as GDPR and HIPAA, is necessary to address these issues, necessitating substantial expenditures in cybersecurity infrastructure.

COVID-19 Impact:

While the pandemic emphasized the significance of rapid and accurate diagnosis, delays in non-urgent diagnostic procedures and the redirection of resources toward COVID-19 testing caused disruptions. Demand for molecular diagnostics, especially PCR-based tests, surged in the industry, but supply chain disruptions and overloaded hospital infrastructures posed problems. Traditional diagnostic settings were also impacted by a shift in emphasis toward telemedicine and remote diagnostics.

The genetic tests segment is expected to be the largest during the forecast period

With the growing popularity of precision medicine, the genetic testing sector held the largest market share. Demand for genetic tests, such as molecular profiling and next-generation sequencing, is rapidly rising. An individual's genetic composition can be fully recognized by these tests, which can detect certain genetic differences, illness susceptibility, and possible treatment reactions. Additionally, the use of genetic tests for illness diagnosis, risk assessment, and treatment planning is being driven by the rising frequency of genetic illnesses and the increasing awareness of individualized healthcare.

The oncology segment is expected to have the highest CAGR during the forecast period

Because molecular testing, liquid biopsies, and genomic profiling have made it possible to identify particular genetic changes and biomarkers linked to various cancer types, the oncology sector is expanding rapidly. With this level of accuracy, oncologists can optimize therapeutic outcomes by customizing treatment plans based on each patient's tumor's unique genetic profile. Accurate diagnostic techniques for oncology are in greater demand due to the rising global prevalence of cancer and our growing understanding of its molecular basis.

Region with largest share:

Because the demand for sophisticated and accurate diagnostic tools has increased due to the rising prevalence of chronic diseases, including cancer and cardiovascular disorders, the Asia-Pacific region is anticipated to hold the largest share of the market over the forecasted period. In addition, the area is experiencing a rise in the middle-class population and healthcare expertise, with a particular emphasis on preventive healthcare practices. Moreover, the precision diagnostic tenets of tailored and targeted interventions for better patient outcomes are in accordance with this movement in healthcare perspectives.

Region with highest CAGR:

The Asia-Pacific region is growing profitably as a result of the rapid advancement in technology and the growing availability of healthcare services. Nations like China, Japan, and India have invested large investments in R&D, infrastructure, and healthcare, providing a climate that is favorable to the adoption of cutting-edge diagnostic technology. The Asia Pacific region will definitely be a major force behind the growth and expansion of the precision diagnostics market on a global scale as it continues to prioritize the development of healthcare infrastructure, invest in research and innovation, and experience a paradigm shift towards precision medicine.

Key players in the market:

Some of the key players in Precision Diagnostics market include Abbott, Bayer AG, Koninklijke Philips N.V., Lantheus Medical Imaging, Inc., Novartis AG, QIAGEN, Quest Diagnostics Incorporated, Sanofi, Siemens Healthineers AG and Swiss Precision Diagnostics GmbH.

Key Developments:

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform.

In September 2023, Abbott signs definitive agreement to acquire Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. As part of the acquisition, Abbott will use Bigfoot Unity with its FreeStyle Libre technology, which uses a customer smartphone app connected to a cloud-based online portal.

In May 2023, Bayer has secured a long-term structured renewable energy credit purchase agreement with Cat Creek Energy that will generate 1.4 terawatt-hours of clean electricity annually, equivalent to the energy consumption of 150,000 households.

Types Covered:

• Direct to Consumer Tests
• Esoteric Tests
• Genetic Tests
• Other Types

Applications Covered:

• Cardiovascular
• Immunology
• Oncology
• Respiratory Diseases
• Other Applications

End Users Covered:

• Clinical Laboratories
• Homecare
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Precision Diagnostics Market, By Type

• 5.1 Introduction
• 5.2 Direct to Consumer Tests
• 5.3 Esoteric Tests
• 5.4 Genetic Tests
• 5.5 Other Types

6 Global Precision Diagnostics Market, By Application

• 6.1 Introduction
• 6.2 Cardiovascular
• 6.3 Immunology
• 6.4 Oncology
• 6.5 Respiratory Diseases
• 6.6 Other Applications

7 Global Precision Diagnostics Market, By End User

• 7.1 Introduction
• 7.2 Clinical Laboratories
• 7.3 Homecare
• 7.4 Hospitals
• 7.5 Other End Users

8 Global Precision Diagnostics Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott
• 10.2 Bayer AG
• 10.3 Koninklijke Philips N.V.
• 10.4 Lantheus Medical Imaging, Inc.
• 10.5 Novartis AG
• 10.6 QIAGEN
• 10.7 Quest Diagnostics Incorporated
• 10.8 Sanofi
• 10.9 Siemens Healthineers AG
• 10.10 Swiss Precision Diagnostics GmbH